ArticleClinical & experimental metastasis1999
Increased levels of alpha6 integrins are associated with the metastatic phenotype of human breast cancer cells.
Article in Clinical & experimental metastasis, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 103 citations in OpenAlex.
- Coexpression of alpha6beta4 integrin and guanine nucleotide exchange factor Net1 identifies node-positive breast cancer patients at high risk for distant metastasis.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2009Trial
- Proximity Labeling and SILAC-Based Proteomic Approach Identifies Proteins at the Interface of Homotypic and Heterotypic Cancer Cell Interactions.Molecular & cellular proteomics : MCP · 2025Article
- Evaluation of Extracellular Matrix Composition to Improve Breast Cancer Modeling.Tissue engineering. Part A · 2021Article
- Autophagy-Related Three-Gene Prognostic Signature for Predicting Survival in Esophageal Squamous Cell Carcinoma.Frontiers in oncology · 2021Article
- ADAM9 Mediates Triple-Negative Breast Cancer Progression via AKT/NF-κB Pathway.Frontiers in medicine · 2020Article
- MicroRNA-143-3p inhibits colorectal cancer metastases by targeting ITGA6 and ASAP3.Cancer science · 2019Article
- Integrin α6/Akt/Erk signaling is essential for human breast cancer resistance to radiotherapy.Scientific reports · 2016Article
- ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models.Molecular cancer · 2016Article
- NADH-Cytochrome b5 Reductase 3 Promotes Colonization and Metastasis Formation and Is a Prognostic Marker of Disease-Free and Overall Survival in Estrogen Receptor-Negative Breast Cancer.Molecular & cellular proteomics : MCP · 2015Article
- The Presence of EpCAM(-)/CD49f(+) Cells in Breast Cancer Is Associated with a Poor Clinical Outcome.Journal of breast cancer · 2015Article
- A cell-ECM screening method to predict breast cancer metastasis.Integrative biology : quantitative biosciences from nano to macro · 2015Article
- Breast Cancer-Derived Extracellular Vesicles: Characterization and Contribution to the Metastatic Phenotype.BioMed research international · 2015Review
- Cell Surface GRP78 Accelerated Breast Cancer Cell Proliferation and Migration by Activating STAT3.PloS one · 2015Article
- Inhibition of Integrin-HER2 signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppression.Oncotarget · 2014Article
- VE-cadherin-independent cancer cell incorporation into the vascular endothelium precedes transmigration.PloS one · 2014Article
- A role for collagen XXIII in cancer cell adhesion, anchorage-independence and metastasis.Oncogene · 2012Article
- Article
- Integrin α5β1 facilitates cancer cell invasion through enhanced contractile forces.Journal of cell science · 2011Article
- Comparing the MRI appearance of the lymph nodes and spleen in wild-type and immuno-deficient mouse strains.PloS one · 2011Article
- A novel steroidal inhibitor of estrogen-related receptor alpha (ERR alpha).Biochemical pharmacology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Integrins play an important role in interactions between cells and the extracellular matrix, and thus have a potential role in metastasis. Expression levels of alpha6, beta1 and beta4 integrin sub-units were measured in a panel of human breast cancer cell lines by RT/PCR, immunoprecipitation and flow cytometry. All the lines expressed alpha6, with the highest levels in the MDA-MB-231 and MDA-MB-435 cells. These grew the most aggressively and were metastastic in nude mice. Low levels of alpha6 protein were measured in breast cancer cells that were poorly tumorigenic and non-metastatic in nude mice, and there was an inverse relationship between ER and alpha6 expression. RT/PCR revealed that all lines expressed the 2 isoforms of alpha6, with the alpha6A isoform generally more abundant than alpha6B isoform. Clones of MDA-MB-435 were isolated by sterile sorting for cells with high or low alpha6 expression, and two variants established from metastases in nude mice were found to differ in alpha6 expression. When injected into nude mice. the alpha6-high variants produced significantly more lung metastases than the alpha6-low variants. beta1was abundant in all lines, while beta4 was not detected in MDA-MB- 134 cells, and in the MDA-MB-435 cells an alternately spliced variant of beta4 was identified. Sequencing of the alternate variant revealed a novel sequence from a splicing event in the cytoplasmic tail of beta4. None of the cells with this variant mRNA expressed detectable levels of beta4 protein. Our results suggest that high alpha6 expression in human breast cancer cells is associated with tumorigenicity and metastatic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.